QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress quietly doubles funding for sickle cell research

S. 735 — Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 · Filed by Tim Scott (R-SC) · 3 cosponsors · Introduced Feb 26, 2025 · Referred to committee

95%
Transparency
Typical bill: 82%
5/100
Hidden-provision risk
Typical bill: 15/100
Public Health Research Funding

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill reauthorizes and expands a federal program that funds research, treatment, and prevention of sickle cell disease and related blood disorders. It increases annual funding from $4.5 million to $8.2 million for fiscal years 2025–2029, broadens the program to include prevention of complications (not just the disease itself), and allows grants in addition to contracts. The bill benefits patients with sickle cell disease, researchers, and treatment providers by increasing resources for a disease that disproportionately affects Black Americans.

Why we flagged it

The bill's sole operative mechanism is reauthorization and expansion of a federal research and treatment program for a specific disease. It is straightforward public health legislation with no hidden provisions or private carve-outs.

What the text implies

  • Shift from 'prevention and treatment' to 'treatment and prevention of complications' may subtly narrow focus from primary prevention (e.g., genetic counseling, carrier screening) to clinical management of existing disease, though the practical impact depends on implementation.
  • Expansion to 'heritable blood disorders' beyond sickle cell (e.g., thalassemia, hemophilia) is stated in the sense-of-Congress clause but not explicitly funded in the reauthorization amount, creating potential ambiguity about whether the $8.2M covers both or primarily sickle cell.

The full analysis lists 3 implications of this text.

Who stands to gain

academic medical centers and research institutions; sickle cell disease treatment and research organizations; public health agencies and state health departments

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the bill title — full-text pass pending · 119th Congress · public record